Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Viewpoint

Strategies for Engineered Negligible Senescence

Zealley B. · de Grey A.D.N.J.

Author affiliations

SENS Foundation, Mountain View, Calif., USA

Related Articles for ""

Gerontology 2013;59:183-189

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Viewpoint

Received: December 28, 2011
Accepted: June 27, 2012
Published online: October 01, 2012
Issue release date: February 2013

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0

ISSN: 0304-324X (Print)
eISSN: 1423-0003 (Online)

For additional information: https://www.karger.com/GER

Abstract

In this viewpoint, we describe the strategies for engineered negligible senescence (SENS) concept - a simple and appealing model for the design of therapeutic interventions able to meaningfully and persistently reverse the deleterious effects of aging. We go on to outline how current or foreseeable biotechnologies could feasibly be employed to repair every currently identified category of pathogenic damage that accumulates over a human lifespan. Then, briefly, we explain why this goal is not only ethically sound, but can in fact be considered to verge on an ethical obligation. Finally, we review recent progress in some key areas of the SENS platform, including proof-of-concept research sponsored by the SENS Foundation, a charity based in California.

© 2012 S. Karger AG, Basel


References

  1. Finch CE: Longevity, Senescence, and the Genome, chapt. 4: Negligible Senescence. Chicago, University of Chicago Press, 1994.
  2. Martínez DE: Mortality patterns suggest lack of senescence in hydra. Exp Gerontol 1998;33:217-225.
  3. Estep PW: Declining asexual reproduction is suggestive of senescence in hydra: comment on Martinez, D.: Mortality patterns suggest lack of senescence in hydra. Exp Gerontol 33, 217-225. Exp Gerontol 2010;45:645-646.
  4. Phoenix C, de Grey ADNJ: A model of aging as accumulated damage matches observed mortality patterns and predicts the life-extending effects of prospective interventions. Age (Dordr) 2007;29:133-189.
  5. de Grey ADNJ, Rae M: Ending Aging: The Rejuvenation Breakthroughs That Could Reverse Human Aging in Our Lifetime. New York, St Martin's Press, 2007.
  6. Vicencio JM, Galluzzi L, Tajeddine N, Ortiz C, Criollo A, Tasdemir E, Morselli E, Ben Younes A, Maiuri MC, Lavandero S, Kroe-mer G: Senescence, apoptosis or autophagy? When a damaged cell must decide its path - a mini-review. Gerontology 2008;54:92-99.
  7. Henriquez M, Armisén R, Stutzin A, Quest AF: Cell death by necrosis, a regulated way to go. Curr Mol Med 2008;8:187-206.
  8. de Grey ADNJ, Campbell FC, Dokal I, Fairbairn LJ, Graham GJ, Jahoda CA, Porter ACG: Total deletion of in vivo telomere elongation capacity: an ambitious but possibly ultimate cure for all age-related human cancers. Ann NY Acad Sci 2004;1019:147-170.
  9. Hetz C: The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol 2012;13:89-102.
  10. Olshansky SJ, Perry D, Miller RA, Butler RN: In pursuit of the longevity dividend. Scientist 2006;20:28-35.
  11. de Grey AD, Ames BN, Andersen JK, Bartke A, Campisi J, Heward CB, McCarter RJ, Stock G: Time to talk SENS: critiquing the immutability of human aging. Ann NY Acad Sci 2002;959:452-462.
  12. Cuervo AM, Dice JF: Age-related decline in chaperone-mediated autophagy. J Biol Chem 2000;275:31505-31513.
  13. Zhang C, Cuervo AM: Restoration of chaperone-mediated autophagy in aging liver improves cellular maintenance and hepatic function. Nat Med 2008;14:959-965.
  14. Butler D, Hwang J, Estick C, Nishiyama A, Kumar SS, Baveghems C, Young-Oxendine HB, Wisniewski ML, Charalambides A, Bahr BA: Protective effects of positive lysosomal modulation in Alzheimer's disease transgenic mouse models. PLoS One 2011;6:e20501.
  15. Rittmann BE, Schloendorn J: Engineering away lysosomal junk: medical bioremediation. Rejuvenation Res 2007;10:359-365.
  16. Paul S, Planque S, Nishiyama Y: Beneficial catalytic immunity to Aβ peptide. Rejuvenation Res 2010;13:179-187.
  17. Banks WA, Farr SA, Morley JE, Wolf KM, Geylis V, Steinitz M: Anti-amyloid-β protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment. Exp Neurol 2007;206:248-256.
  18. Wang YY, Lui PC, Li JY: Receptor-mediated therapeutic transport across the blood-brain barrier. Immunotherapy 2009;1:983-993.
  19. Coles LS, Young RD: Supercentenarians and transthyretin amyloidosis: the next frontier of human life extension. Prev Med 2012;54(suppl):S9-S11.
  20. Röthlisberger D, Khersonsky O, Wollacott AM, Jiang L, DeChancie J, Betker J, Gallaher JL, Althoff EA, Zanghellini A, Dym O, Albeck S, Houk KN, Tawfik DS, Baker D: Kemp elimination catalysts by computational enzyme design. Nature 2008;453:190-195.
  21. Macchiarini P, Jungebluth P, Go T, Asnaghi MA, Rees LE, Cogan TA, Dodson A, Martorell J, Bellini S, Parnigotto PP, Dickinson SC, Hollander AP, Mantero S, Conconi MT, Birchall MA: Clinical transplantation of a tissue-engineered airway. Lancet 2008;372:2023-2030.
  22. Jakab K, Norotte C, Marga F, Murphy K, Vunjak-Novakovic G, Forgacs G: Tissue engineering by self-assembly and bio-printing of living cells. Biofabrication 2010;2:022001.
  23. de Grey ADNJ: Mitochondrial gene therapy: an arena for the biomedical use of inteins. Trends Biotechnol 2000;18:394-399.
  24. Kaltimbacher V, Bonnet C, Lecoeuvre G, Forster V, Sahel JA, Corral-Debrinski M: mRNA localization to the mitochondrial surface allows the efficient translocation inside the organelle of a nuclear recoded ATP6 protein. RNA 2006;12:1408-1417.

Article / Publication Details

First-Page Preview
Abstract of Viewpoint

Received: December 28, 2011
Accepted: June 27, 2012
Published online: October 01, 2012
Issue release date: February 2013

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0

ISSN: 0304-324X (Print)
eISSN: 1423-0003 (Online)

For additional information: https://www.karger.com/GER


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.